Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Tilray Brands

Cannabis stocks advanced Thursday, helped by news that a key Senate committee could soon vote to advance a widely followed bill that aims to make it easier for the financial industry to work with cannabis companies.

Cannabis stocks gain as banking bill finds traction in Senate, but House OK looks challenging

AFC Gamma

Cannabis stocks may be some of the most controversial investing ideas. Yet, they could also become some of the most profitable.That reality may happen if cannabis can be rescheduled and federally legalized.

Investing in Cannabis Stocks? 3 Marijuana Companies That Could Get a Massive Rescheduling Boost

Village Farms International

We're glad you're here to learn about this week's top marijuana stocks, poised to see significant increases in September 2023. As the cannabis industry evolves, savvy investors seek opportunities while considering risk. This study combines technical analysis with lessons from the rapidly expanding cannabis industries in the United States and Canada.

Green Investments: Top Canadian Marijuana Stocks for September 2023

Over the weekend, the White House threw its support behind legalizing medical marijuana. Yesterday, the Senate Majority Leader said he will push for marijuana banking reform.

Why Canopy Growth Stock Keeps On Growing

Aurora Cannabis

Cronos Group

Easterly Government Properties

Harte Hanks

Philip Morris

Constellation Brands

Stocks that deal in cannabis are rising as the U.S. government moves toward re-classifying marijuana. The Department of Health and Human Services (HHS) has asked the Drug Enforcement Administration (DEA) to consider moving marijuana from Schedule I to Schedule III.

Why Are Cannabis Stocks Still Up Today?

Innovative Industrial Properties

Chicago Atlantic Real Estate Finance

SNDL Inc.

Curaleaf Holdings Inc. OTCMKTS: CURLF,  Innovative Industrial Properties Inc. NYSE: IIPR and Tilray Inc. NASDAQ: TLRY were among cannabis stocks jumping higher after the Department of Health and Human Services recommended that marijuana no longer be classified as a Schedule 1 drug.

Will This New Development Mean A Big Rally In Cannabis Stocks?

Cannabis stocks have come roaring back on recent news of major decriminalization progress at the federal level. The big question now for anyone who owns marijuana stocks or is considering the sector: Is there more upside left?

Cannabis stocks are still a buy despite recent double-digit gains

Last month, the Department of Health and Human Services suggested easing regulations on marijuana use. The Drug Enforcement Agency has final say on that -- but its boss, President Joe Biden, now says he supports medical marijuana legalization.

Why Marijuana Stocks Keep Growing Higher Tuesday

OrganiGram Holdings Inc.

Trulieve Cannabis Corp.

Cannabis stocks continued to move higher following the Labor Day long weekend after the U.S. Department of Health and Human Services (HHS) last week recommended reclassifying marijuana as a lower-risk drug.

Cannabis stock rally continues on marijuana rescheduling hopes

Canopy Growth Corporation's stock price rallied nearly 50% based on the news that the US Department of Health and Human Services recommended rescheduling cannabis to Schedule III. Other Canadian cannabis LPs and US cannabis support stocks also saw rallies, with Tilray, Village Farms, and Grow Generation all experiencing gains. The rescheduling of cannabis and the passage of the Safe Banking Act could lead to a larger cannabis stock rally and benefit US multi-state cannabis operators.

Canopy Growth Rallies On Possible Rescheduling Of Cannabis: Time To Buy

Cannabis stocks are on track to finish the week higher boosted by the news that the U.S. Department of Health and Human Services (HHS) has recommended reclassifying marijuana as a lower-risk drug.

Cannabis stocks set to end week on a high following marijuana rescheduling recommendation

Roundhill Cannabis ETF

When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.

Time to Get High on Pot Stocks? (3 Catalysts)

Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.

3 Cannabis Stocks Soaring on HHS' Recommendation to DEA

The recommendation is part of a larger marijuana reform plan announced by the Biden Administration last year.

Cannabis Stocks Surge After HHS Recommends Classifying Marijuana As Lower-Risk Drug

If marijuana is downgraded to a Schedule III drug, it could be a huge boost to a struggling industry.

U.S. health officials want to loosen marijuana restrictions. Here's what it means

GrowGeneration Corp

The U.S. Department of Health and Human Services just recommended easing regulations on marijuana. The U.S. Drug Enforcement Agency may (or may not) take that advice.

Why Marijuana Stocks Are Glowing Green on Thursday

Global X Cannabis ETF

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

Cannabis stocks are up on Thursday as investors in the market react to news marijuana may be downgraded from a Schedule I drug. According to insiders, a member of the Department of Health and Human Services is seeking a drop in the drug from Schedule I to Schedule III.

Why Are Cannabis Stocks TLRY, ACB, CGC, CURLF Up Today?

Shares of marijuana companies climbed as much as 14% in morning trading on Thursday after the Department of Health and Human Services recommended its reclassification as a lower-risk substance following an 11-month review.

Pot firms gain as US move to ease curbs boosts sentiment

The U.S. government appears finally to be ready to review its categorization of marijuana as a dangerous drug, reviving hope among investors and marijuana producers for an industry that took off like a rocket five years ago before sinking like a rock less than two years later.

Will a Change to US Marijuana Policy Save Any of the Weed Companies?

Canopy Growth issued 15.2 million common shares to Les Serres Stephane Bertrand as part of an amended agreement for the Canadian cannabis company to buy a 45% stake in Les Serres Vert Cannabis.

Canopy Growth amends agreement to buy remaining stake of Les Serres Vert Cannabis

According to a media report, a top federal health official has formally requested the reclassification of marijuana. This indicates high-level government support for drug law reform, at least for cannabis.

Why Canopy Growth Stock Was on Fire Today

The Drug Enforcement Agency received an official recommendation to downgrade marijuana.  Currently, pot is classified as a Schedule I drug, on par with heroin.

Pot stocks jump as federal agency reportedly seeks to downgrade cannabis from the hard-drug category

That move could potentially expand the market for cannabis, sending shares of Canopy Growth, Tilray Brands and Cronos Group higher.

HHS calls for easing restrictions on marijuana, sending cannabis stocks higher

The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law from Schedule I now, according to a report by Bloomberg. Cannabis stocks are rallying, with the AdviserShares Pure US Cannabis ETF MSOS, +18.76% up by nearly 33%, and the ETFMG Alternative Harvest ETF MJ, +10.27% up by 19.5%.

News for Canopy Growth Stock (CGC)